Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab + Erlotinib in MET+ Squamous Cell Lung Cancer (Lung-Map S1400E)
NCT02926638Phase 3Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rilotumumab in squamous cell carcinoma of the lung (LSCC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Investigator-assessed Progression-free Survival at 18 months and Overall Survival at 3 years. Started Jun 2014; status: terminated.
02
Drugs
rilotumumab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02926638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926638.